Our researchers conduct clinical trials to improve care for many types of cancer.
Clinical trials are research studies for the purpose of evaluating a medical, surgical or behavioural intervention in which patients may volunteer to take part. We embark on clinical trials to find better ways to prevent, diagnose and treat cancer.
Clinical trials are part of a longitudinal process, which include studies to assess the safety, efficacy and effectiveness of a new treatment or drug versus the standard treatment, or to test ways to find a disease early, sometimes before any symptoms appear. Your doctor may offer you a clinical trial as a treatment option.
You may reach out to our Clinical Trial Unit if you are interested to find out more about the criteria or participate in an active clinical trial.
| Study Title | Target Group | Current Status |
|---|---|---|
| A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma. | Relapsed or Refractory Multiple Myeloma | Actively Recruiting |
| A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP). | Primary Immune Thrombocytopenia (ITP) | Recruitment closed. Patients under treatment phase. |
| A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator-selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia. | Chronic Myelogenous Leukemia | Treatment Phase |
| A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). | Diffuse Large B-Cell Lymphoma (DLBCL) | Follow-up Phase |
| A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with DLBCL. | Diffuse Large B-Cell Lymphoma | Actively Recruiting |
| Site 458-405: A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab versus Standard of Care Therapy in Participants with Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma. | Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma | Actively Recruiting |
| Site 458-505: A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab in Combination with Lenalidomide Versus Rituximab in Combination with Lenalidomide in Relapsed/Refractory Participants with Follicular Lymphoma and Marginal Zone Lymphoma. | Follicular Lymphoma and Marginal Zone Lymphoma | Actively Recruiting |
KKLIU 0399 / EXP 31.12.2025
SJP Medical Centres Sdn. Bhd.
(Formerly known as RSD Hospitals Sdn. Bhd.)
Registration No: 198901004482 (181788-D)
Copyright © 2024 Subang Jaya Medical Centre - All Rights Reserved
